{"id":"NCT02943564","sponsor":"Naurex, Inc, an affiliate of Allergan plc","briefTitle":"A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-01","primaryCompletion":"2018-12-12","completion":"2018-12-18","firstPosted":"2016-10-24","resultsPosted":"2019-12-27","lastUpdate":"2019-12-27"},"enrollment":658,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Rapastinel","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rapastinel 225 mg","type":"EXPERIMENTAL"},{"label":"Rapastinel 450 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study","timeFrame":"Baseline and 3 Weeks","effectByArm":[{"arm":"Placebo","deltaMin":-4.9,"sd":0.59},{"arm":"Rapastinel 225 mg","deltaMin":-4.8,"sd":0.6},{"arm":"Rapastinel 450 mg","deltaMin":-5.4,"sd":0.6}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8862"},{"comp":"OG001 vs OG002","p":"0.5772"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":66,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.AllerganClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":217},"commonTop":["Headache"]}}